Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29456798 | 1.00 | TRPA1 (0.42) | TRPA1ATMCYP2A6CYP1A2TSHR | |
| Tetrahydrofuran SCHEMBL29148622 | 0.84 | CNR2 (0.33) | TRPA1ATMALDH1A1SMN1; SMN2 | |
| SCHEMBL29881812 | 0.79 | — | — | |
| SCHEMBL1137018 | 0.79 | TRPA1 (0.46) | TRPA1ATMCYP2A6CYP1A2TSHR | |
| SCHEMBL959600 | 0.79 | — | — | |
| SCHEMBL1125226 | 0.76 | ACHE (0.37) | ACHEALDH1A1SMN1; SMN2 | |
| SCHEMBL1314594 | 0.75 | TRPA1 (0.42) | TRPA1ATMCYP2A6CYP1A2TSHR | |
| SCHEMBL1317819 | 0.75 | TRPA1 (0.42) | TRPA1ATMCYP2A6CYP1A2TSHR | |
| SCHEMBL7105911 | 0.73 | CA1 (0.42) | TSHRALDH1A1CA1CA2CA7 | |
| SCHEMBL14892395 | 0.71 | TSHR (0.39) | CYP1A2TSHRACHEALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677636-B | Preparation method of 2, 3',4' -biphenyl tetracarboxylic dianhydride | 天津众泰材料科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-115677636-A | Preparation method of 2, 3',4' -biphenyl tetracarboxylic dianhydride | 天津众泰材料科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-115028519-A | Novel synthesis method of dexmedetomidine intermediate 2, 3-dimethylacetophenone | 南京亿华药业有限公司 | 2022-09-09 | — | — | CN | claimed |
| WO-2021012478-A1 | HYDROGENATION ANNULE [12] AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR | 清华大学 | 2021-01-28 | — | — | WO | claimed |
| WO-2021012479-A1 | HYDROGENATED CYCLIC [8] AROMATIC HYDROCARBON COMPOUND AND PREPARATION METHOD THEREFOR | 清华大学 | 2021-01-28 | — | — | WO | claimed |
| CN-112194626-A | Synthesis method of medetomidine | 康普药业股份有限公司 | 2021-01-08 | — | — | CN | claimed |
| CN-110372468-B | Hydrogenated endless [8] arene compound and preparation method thereof | 清华大学 | 2020-11-10 | — | — | CN | claimed |
| CN-110372469-B | Hydrogenated cyclo [12] arene compound and preparation method thereof | 清华大学 | 2020-09-08 | — | — | CN | claimed |
| CN-100548950-C | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-10-14 | — | — | CN | claimed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| EP-4506340-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | Obshestvo s Ogranichennoj Otvetstvennostju "Vikzdorove Zhivotnyh" (RU) | 2025-02-12 | — | — | EP | disclosed |
| US-4584383-A | Substituted 2-mercapto-imidazoles and their preparation | FARMOS YHTYMA-OY (FI) | 1986-04-22 | — | — | US | disclosed |
| EP-0146228-A1 | Substituted 2-mercapto-imidazoles and their preparation and use | Farmos-Yhtyma Oy (FI) | 1985-06-26 | — | — | EP | disclosed |
| US-3969522-A | Diaryl-pyridyl-imidazole methanes for treating mycotic infections | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | TRPA1 2739/4885ATM 4854/4885CYP2A6 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.